Wednesday, January 30th, 2013
09:30am Light refreshments, juice, coffee, and tea
10:00am Welcome, meeting charge and overall process/methodology, and introductions
10:15am Brief Overview of the Chemotherapy Shortage, Dr. Yoram Unguru
Morning Session – Decision-making & Allocation Within Institutions
10:30am Dealing With Shortages at the Institutional Level, Dr. Philip Rosoff
10:45am Group Discussion (Facilitators: Steven Joffe, Yoram Unguru)
The discussion will focus on decision-making and allocation decisions at the “local level,” i.e., within individual institutions. Topics for discussion include information needs, institutional obstacles, ethical challenges including possible preferential access for clinical trial participants, relevant stakeholders, ethical frameworks for decision-making, and prioritization of scarce drugs within institutions.
12:00pm Working Lunch
12:20pm Regional Approaches to Coordinating Scarce Resources, Mr. Howard Gwon
12:30pm Federal Response to Drug Shortages, Mr. W. Nicholson Price II
Afternoon Session – Coordination and Cooperation Across Institutions
1:00pm Cooperative Group Response to the Drug Shortage, Dr. Brooke Bernhardt
1:15pm Comments, Dr. Peter Adamson
1:20pm Rationale for Coordination, Dr. Matthew DeCamp
1:30pm Group Discussion – Rationale for and challenges to coordination (Facilitators: Yoram Unguru, Matt DeCamp)
The discussion will focus on the necessity for cross-institutional coordination; ethical justifications and a framework for coordination; clinician/researcher’s obligations to privilege one’s own patients; locus of responsibility for coordination (role of government, industry, cooperative groups, and professional societies); and obstacles to coordination (e.g., stockpiling and the gray market).
- Should we coordinate? Why or why not?
- How might we coordinate?
- Barriers to coordination
2:45pm Discussion – How should we coordinate?
- Institutional structures & processes for coordination
- Role of professional societies
- Role of cooperative groups
- Role of other stakeholders (government, industry, advocacy organizations)
3:45pm Summary, conclusions, and next steps